Vascular dysfunction and obesity

Obesity and Cardiovascular Disease

Volumn , Issue , 2006, Pages 93-120

  Mather, Kieren J ^a   Baron, Alain D ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882554058     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (202)

1. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106:653-658.
2. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104:2673-2678.
3. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899-1906.
4. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
7. Meigs JB, Wilson PW, Nathan DM, D’Agostino RB Sr, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003; 52:2160-2167.
8. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108:414-419.
9. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13:3S-10S.
10. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care 1999; 22:696-699.
11. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
12. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000; 20:538-544.
13. Bao W, Srinivasan SR, Berenson GS. Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults. The Bogalusa Heart Study. Circulation 1996; 93:54-59.
14. Ruige JB, Assendelft WJJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease—a meta-analysis. Circulation 1998; 97:996-1001.
15. Cruz ML, Bergman RN, Goran MI. Unique effect of visceral fat on insulin sensitivity in obese Hispanic children with a family history of type 2 diabetes. Diabetes Care 2002; 25:1631-1636.
16. Goran MI, Bergman RN, Gower BA. Influence of total vs. visceral fat on insulin action and secretion in African American and white children. Obes Res 2001; 9:423-431.
17. Mittelman SD, Van Citters GW, Kirkman EL, Bergman RN. Extreme insulin resistance of the central adipose depot in vivo. Diabetes 2002; 51:755-761.
18. Wagenknecht LE, Langefeld CD, Scherzinger AL, et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2003; 52:2490-2496.
19. Laight DW, Desai KM, Anggard EE, Carrier MJ. Endothelial dysfunction accompanies a pro-oxidant, pro-diabetic challenge in the insulin resistant, obese Zucker rat in vivo. Eur J Pharmacol 2000; 402:95-99.
20. McNamee CJ, Kappagoda CT, Kunjara R, Russell JC. Defective endotheliumdependent relaxation in the JCR: LA-corpulent rat. Circ Res 1994; 74: 1126-1132.
21. Perticone F, Ceravolo R, Candigliota M, et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001; 50:159-165.
22. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97:2601-2610.
23. Tack CJJ, Ong MKE, Lutterman JA, Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia 1998; 41:569-576.
24. Vigili de Kreutzenberg S, Kiwanuka E, Tiengo A, Avogaro A. Visceral obesity is characterized by impaired nitric oxide-independent vasodilation. Eur Heart J 2003; 24:1210-1215.
25. Higashi Y, Oshima T, Sasaki N, et al. Relationship between insulin resistance and endothelium-dependent vascular relaxation in patients with essential hypertension. Hypertension 1997; 29:280-285.
26. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
27. Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784.
28. Anastasiou E, Lekakis JP, Alevizaki M, et al. Impaired endotheliumdependent vasodilatation in women with previous gestational diabetes. Diabetes Care 1998; 21:2111-2115.
29. Knock GA, McCarthy AL, Lowy C, Poston L. Association of gestational diabetes with abnormal maternal vascular endothelial function. Br J Obstet Gynaecol 1997; 104:229-234.
30. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001; 103:1410-1415.
31. Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995; 96:786-792.
32. Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 2000; 35:507-511.
33. Olsen MH, Andersen UB, Wachtell K, Ibsen H, Dige-Petersen H. A possible link between endothelial dysfunction and insulin resistance in hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Blood Press 2000; 9:132-139.
34. Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996; 93:1331-1333.
35. Serne EH, Stehouwer CD, ter Maaten JC, et al. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 1999; 99:896-902.
36. Utriainen T, Makimattila S, Virkamaki A, Bergholm R, Yki-Jarvinen H. Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects. Diabetologia 1996; 39:1477-1482.
37. Verma S, Bhanot S, Yao L, McNeill JH. Defective endothelium-dependent relaxation in fructose-hypertensive rats. Am J Hypertens 1996; 9:370-376.
38. Verma S, Bhanot S, Yao L, McNeill JH. Vascular insulin resistance in fructose-hypertensive rats. Eur J Pharmacol 1997; 322:R1-R2.
39. Baron AD, Zhu JS, Zhu JH, Weldon H, Maianu L, Garvey WT. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. J Clin Invest 1995; 96: 2792-2801.
40. Gabriely I, Yang XM, Cases JA, Ma XH, Rossetti L, Barzilai N. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis 2002; 160:115-122.
41. Holmang A, Nilsson C, Niklasson B, Lonroth P. Induction of insulin resistance by glucosamine reduces blood flow but not interstitial levels of either glucose or insulin. Diabetes 1999; 48:106-111.
42. Patti ME, Virkamaki A, Landaker EJ, Kahn CR, Yki-Jarvinen H. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Diabetes 1999; 48:1562-1571.
43. Abe H, Yamada N, Kamata K, et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 1998; 101:1784-1788.
44. Bruning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998; 2:559-569.
45. Vicent D, Ilany J, Kondo T, et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 2003; 111: 1373-1380.
46. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941-946.
47. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277:25863-25866.
48. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 1999; 892:146-154.
49. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88: 3236-3240.
50. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86:3815-3819.
51. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42:231-234.
52. Clerk LH, Rattigan S, Clark MG. Lipid infusion impairs physiologic insulinmediated capillary recruitment and muscle glucose uptake in vivo. Diabetes 2002; 51:1138-1145.
53. Mason TM, Goh T, Tchipashvili V, et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes 1999; 48:524-530.
54. de Kreutzenberg SV, Crepaldi C, Marchetto S, et al. Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition. J Clin Endocrinol Metab 2000; 85:793-798.
55. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997; 100:1230-1239.
56. Egan BM, Lu G, Greene EL. Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Prostaglandins Leukot Essent Fatty Acids 1999; 60:411-420.
57. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000; 49:1231-1238.
58. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91.
59. Sewter CP, Digby JE, Blows F, Prins J, O’Rahilly S. Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. J Endocrinol 1999; 163:33-38.
60. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 272-278.
61. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95:2409-2415.
62. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000; 11:212-217.
63. Hollenberg SM, Cunnion RE, Parrillo JE. The effect of tumor necrosis factor on vascular smooth muscle. In vitro studies using rat aortic rings. Chest 1991; 100:1133-1137.
64. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994; 266: H2535-H2541.
65. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000; 85:1316-1319.
66. Arvola P, Wu X, Kahonen M, et al. Exercise enhances vasorelaxation in experimental obesity associated hypertension. Cardiovasc Res 1999; 43: 992-1002.
67. Lavrencic A, Salobir BG, Keber I. Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. Arterioscler Thromb Vasc Biol 2000; 20:551-555.
68. Fuchsjager-Mayrl G, Pleiner J, Wiesinger GF, et al. Exercise training improves vascular endothelial function in patients with type 1 diabetes. Diabetes Care 2002; 25:1795-1801.
69. Maiorana A, O’Driscoll G, Cheetham C, et al. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J Am Coll Cardiol 2001; 38:860-866.
70. Bergholm R, Tiikkainen M, Vehkavaara S, et al. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care 2003; 26:1667-1672.
71. Ebeling P, Teppo AM, Koistinen HA, et al. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes. Diabetologia 1999; 42:1433-1438.
72. Ferri C, Desideri G, Valenti M, et al. Early upregulation of endothelial adhesion molecules in obese hypertensive men. Hypertension 1999; 34:568-573.
73. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105:804-809.
74. Bailey CJ, Path MRC, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
75. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137:25-33.
76. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002; 51:2420-2425.
77. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51:2074-2081.
78. Ruderman NB, Cacicedo JM, Itani S, et al. Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem Soc Trans 2003; 31: 202-206.
79. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108:1167-1174.
80. Verma S, Yao L, Dumont AS, McNeill JH. Metformin treatment corrects vascular insulin resistance in hypertension. J Hypertens 2000; 18:1445-1450.
81. Abbink EJ, Pickkers P, Jansen van Rosendaal A, et al. Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients. Diabet Med 2002; 19:136-143.
82. Mather K, Verma S, Anderson T. Effect of modulating insulin resistance on endothelial function in type 2 diabetes mellitus [abstr]. Circulation 1999; 100:I-832.
83. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol 2001; 12:511-518.
84. Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:576-580.
85. Caballero AE, Saouaf R, Lim SC, et al. The effects of troglitazone, an insulinsensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003; 52:173-180.
86. Watanabe Y, Sunayama S, Shimada K, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb 2000; 7:159-163.
87. Yamagishi T, Saito Y, Nakamura T, et al. Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. Hypertens Res 2001; 24:705-709.
88. Martin-Nizard F, Furman C, Delerive P, et al. Peroxisome proliferatoractivated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol 2002; 40: 822-831.
89. Phillips JW, Barringhaus KG, Sanders JM, et al. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation 2003; 108:1994-1999.
90. Tao L, Liu HR, Gao E, et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-{gamma} agonist in hypercholesterolemia. Circulation 2003; 108:2805-2811.
91. Toriumi Y, Hiraoka M, Watanabe M, Yoshida M. Pioglitazone reduces monocyte adhesion to vascular endothelium under flow by modulating RhoA GTPase and focal adhesion kinase. FEBS Lett 2003; 553:419-422.
92. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48:1448-1453.
93. Yoshimoto T, Naruse M, Shizume H, et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 1999; 145:333-340.
94. Naderali EK, Pickavance LC, Wilding JP, Doyle PJ, Williams G. Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. Eur J Pharmacol 2001; 416:133-139.
95. Takase H, Hakamata M, Toriyama T, et al. Effect of troglitazone on endothelial function in type 2 diabetic patients. Arzneimittelforschung 2002; 52:34-38.
96. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998; 47:810-814.
97. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Ann Rev Med 1997; 48:489-509.
98. Schiffrin EL. The endothelium and control of blood vessel function in health and disease. Clin Invest Med 1994; 17:602-620.
99. Catalano M, Carzaniga G, Perilli E, et al. Basal nitric oxide production is not reduced in patients with noninsulin-dependent diabetes mellitus. Vasc Med 1997; 2:302-305.
100. Sharma AC, Fogelson BG, Nawas SI, et al. Elevated coronary endothelin-1 but not nitric oxide in diabetics during CABG. Ann Thorac Surg 1999; 67: 1659-1663.
101. Honing ML, Morrison PJ, Banga JD, Stroes ES, Rabelink TJ. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 1998; 14:241-249.
102. Kurioka S, Koshimura K, Murakami Y, Nishiki M, Kato Y. Reverse correlation between urine nitric oxide metabolites and insulin resistance in patients with type 2 diabetes mellitus. Endocr J 2000; 47:77-81.
103. Martina V, Bruno GA, Trucco F, et al. Platelet cNOS activity is reduced in patients with IDDM and NIDDM. Thromb Haemost 1998; 79:520-522.
104. Avogaro A, Toffolo G, Kiwanuka E, de Kreutzenberg SV, Tessari P, Cobelli C. L-Arginine-nitric oxide kinetics in normal and type 2 diabetic subjects: a stable-labelled 15N arginine approach. Diabetes 2003; 52:795-802.
105. Shinozaki K, Nishio Y, Okamura T, et al. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res 2000; 87:566-573.
106. Cavarape A, Feletto F, Mercuri F, Quagliaro L, Daman G, Ceriello A. Highfructose diet decreases catalase mRNA levels in rat tissues. J Endocrinol Invest 2001; 24:838-845.
107. Faure P, Rossini E, Wiernsperger N, Richard MJ, Favier A, Halimi S. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes 1999; 48:353-357.
108. Shinozaki K, Hirayama A, Nishio Y, et al. Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. J Am Coll Cardiol 2001; 38:1821-1828.
109. Garg R, Kumbkarni Y, Aljada A, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flowmediated vasodilatation in obese subjects. Hypertension 2000; 36:430-435.
110. Facchini F, Coulston AM, Reaven GM. Relation between dietary vitamin intake and resistance to insulin-mediated glucose disposal in healthy volunteers. Am J Clin Nutr 1996; 63:946-949.
111. Facchini FS, Humphreys MH, DoNascimento CA, Abbasi F, Reaven GM. Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols. Am J Clin Nutr 2000; 72:776-779.
112. Dagenais GR, Yusuf S, Bourassa MG, et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001; 104:522-526.
113. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:154-160.
114. Ishii M, Shimizu S, Nagai T, Shiota K, Kiuchi Y, Yamamoto T. Stimulation of tetrahydrobiopterin synthesis induced by insulin: possible involvement of phosphatidylinositol 3-kinase. Int J Biochem Cell Biol 2001; 33:65-73.
115. Ceolotto G, Gallo A, Miola M, et al. Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes 1999; 48:1316-1322.
116. Esberg LB, Ren J. Role of nitric oxide, tetrahydrobiopterin and peroxynitrite in glucose toxicity-associated contractile dysfunction in ventricular myocytes. Diabetologia 2003.
117. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endotheliumdependent relaxation by activating protein kinase C. J Clin Invest 1991; 87: 1643-1648.
118. Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with insulindependent diabetes mellitus. J Am Coll Cardiol 1998; 31:552-557.
119. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulindependent diabetes mellitus. J. Clin Invest 1996; 97:22-28.
120. Brunner F, Wolkart G, Pfeiffer S, Russell JC, Wascher TC. Vascular dysfunction and myocardial contractility in the JCR: LA-corpulent rat. Cardiovasc Res 2000; 47:150-158.
121. Bagi Z, Koller A. Lack of nitric oxide mediation of flow-dependent arteriolar dilation in type I diabetes is restored by sepiapterin. J Vasc Res 2003; 40: 47-57.
122. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 2000; 43:1435-1438.
123. Boger RH, Bode-Boger SM. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin Thromb Hemost 2000; 26:539-545.
124. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002; 45:1609-1616.
125. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003; 166:279-284.
126. Paiva H, Laakso J, Lehtimaki T, Isomustajarvi M, Ruokonen I, Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003; 41:219-222.
127. Surdacki A, Nowicki M, Sandmann J, et al. Effects of acute euglycemic hyperinsulinemia on urinary nitrite/nitrate excretion and plasma endothelin-1 levels in men with essential hypertension and normotensive controls. Metabolism 1999; 48:887-891.
128. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287:1420-1426.
129. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106:987-992.
130. Xiong Y, Fu YF, Fu SH, Zhou HH. Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes. J Cardiovasc Pharmacol 2003; 42:191-196.
131. Asagami T, Abbasi F, Stuelinger M, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51:843-846.
132. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Angiotensinconverting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J 2002; 66:811-815.
133. Levin ER. Endothelins. N Engl J Med 1995; 333:356-363.
134. Anfossi G, Cavalot F, Massucco P, et al. Insulin influences immunoreactive endothelin release by human vascular smooth muscle cells. Metabolism 1993; 42:1081-1083.
135. Hu RM, Levin ER, Pedram A, Frank HJ. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 1993; 42: 351-358.
136. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48: 1856-1862.
137. Cardillo C, Nambi SS, Kilcoyne CM, et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 1999; 100:820-825.
138. Donatelli M, Colletti I, Bucalo ML, Russo V, Verga S. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res 1994; 25:159-164.
139. Donatelli M, Hoffmann E, Colletti I, et al. Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease. Acta Diabetol 1996; 33:246-248.
140. Ferri C, Bellini C, Desideri G, et al. Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp Clin Endocrinol Diabetes 1997; 105:38-40.
141. Ferri C, Bellini C, Desideri G, et al. Plasma endothelin-1 levels in obese hypertensive and normotensive men. Diabetes 1995; 44:431-436.
142. Juan CC, Fang VS, Kwok CF, Perng JC, Chou YC, Ho LT. Exogenous hyperinsulinemia causes insulin resistance, hyperendothelinemia, and subsequent hypertension in rats. Metabolism 1999; 48:465-471.
143. Bertello P, Veglio F, Pinna G, et al. Plasma endothelin in NIDDM patients with and without complications. Diabetes Care 1994; 17:574-577.
144. Kanno K, Hirata Y, Shichiri M, Marumo F. Plasma endothelin-1 levels in patients with diabetes mellitus with or without vascular complication. J Cardiovasc Pharmacol 1991; 17:S475-S476.
145. Mangiafico RA, Malatino LS, Santonocito M, Spada RS. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs. Int Angiol 1998; 17:97-102.
146. Piatti PM, Monti LD, Galli L, et al. Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism 2000; 49:748-752.
147. Ferri C, Bellini C, Desideri G, De Mattia G, Santucci A. Endogenous insulin modulates circulating endothelin-1 concentrations in humans. Diabetes Care 1996; 19:504-506.
148. Ferri C, Carlomagno A, Coassin S, et al. Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men. Diabetes Care 1995; 18:226-233.
149. Gottsater A, Rendell M, Anwaar I, Lindgarde F, Hulthen UL, Mattiasson I. Increasing neopterin and decreasing endothelin-1 in plasma during insulin infusion in women. Scand J Clin Lab Invest 1999; 59:417-424.
150. Katsumori K, Wasada T, Saeki A, Naruse M, Omori Y. Lack of acute insulin effect on plasma endothelin-1 levels in humans. Diabetes Res Clin Pract 1996; 32:187-189.
151. Katakam PV, Pollock JS, Pollock DM, Ujhelyi MR, Miller AW. Enhanced endothelin-1 response and receptor expression in small mesenteric arteries of insulin-resistant rats. Am J Physiol Heart Circ Physiol 2001; 280:H522-H527.
152. Verma S, Skarsgard P, Bhanot S, Yao L, Laher I, McNeill JH. Reactivity of mesenteric arteries from fructose hypertensive rats to endothelin-1. Am J Hypertens 1997; 10:1010-1019.
153. Evans T, Deng DX, Chen S, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes 2000; 49:662-666.
154. Wu SQ, Hopfner RL, McNeill JR, Wilson TW, Gopalakrishnan V. Altered paracrine effect of endothelin in blood vessels of the hyperinsulinemic, insulin resistant obese Zucker rat. Cardiovasc Res 2000; 45:994-1000.
155. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-740.
156. Blochl-Daum B, Vierhapper H, Eichler HG, Waldhausl W. Endothelininduced venoconstriction is unaffected by type 2-diabetes: in vivo effect of histamine on the endothelin action on veins. Arch Int Pharmacodyn Ther 1992; 316:90-96.
157. McAuley DF, McGurk C, Nugent AG, Hanratty C, Hayes JR, Johnston GD. Vasoconstriction to endothelin-1 is blunted in non-insulin-dependent diabetes: a dose-response study. J Cardiovasc Pharmacol 2000; 36:203-208.
158. McAuley DF, Nugent AG, McGurk C, Maguire S, Hayes JR, Johnston GD. Vasoconstriction to endogenous endothelin-1 is impaired in patients with Type II diabetes mellitus. Clin Sci (Colch) 2000; 99:175-179.
159. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002; 106:1783-1787.
160. Mather K, Steinberg H, Mirzamohammadi B, Hook G, Baron A. ET-1A receptor blockade improves endothelium-dependent vasodilation in insulin resistant obese and Type 2 diabetic patients [abstr]. Diabetes 2000; 49(suppl 1):A143.
161. Mather K, Mirzamohammadi B, Lteif A, Steinberg H, Baron A. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and Type 2 diabetes mellitus. Diabetes 2002; 51:3517-3523.
162. Flowers MA, Wang Y, Stewart RJ, Patel B, Marsden PA. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. Am J Physiol 1995; 269:H1988-H1997.
163. Marsen TA, Egink G, Suckau G, Baldamus CA. Tyrosine-kinase-dependent regulation of the nitric oxide synthase gene by endothelin-1 in human endothelial cells. Pflugers Arch 1999; 438:538-544.
164. Schena M, Mulatero P, Schiavone D, et al. Vasoactive hormones induce nitric oxide synthase mRNA expression and nitric oxide production in human endothelial cells and monocytes. Am J Hypertens 1999; 12:388-397.
165. Hopfner RL, Hasnadka RV, Wilson TW, McNeill JR, Gopalakrishnan V. Insulin increases endothelin-1-evoked intracellular free calcium responses by increased ET(A) receptor expression in rat aortic smooth muscle cells. Diabetes 1998; 47:937-944.
166. Goligorsky MS, Tsukahara H, Magazine H, Andersen TT, Malik AB, Bahou WF. Termination of endothelin signaling: role of nitric oxide. J Cell Physiol 1994; 158:485-494.
167. Jiang ZY, Zhou QL, Chatterjee A, et al. Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes 1999; 48:1120-1130.
168. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonistmediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97:752-756.
169. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312.
170. Kimura K, Tsuda K, Baba A, et al. Involvement of nitric oxide in endotheliumdependent arterial relaxation by leptin. Biochem Biophys Res Commun 2000; 273:745-749.
171. Lembo G, Vecchione C, Fratta L, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49:293-297.
172. Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002; 51:168-173.
173. Quehenberger P, Exner M, Sunder-Plassmann R, et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002; 90:711-718.
174. Clarke KJ, Zhong Q, Schwartz DD, Coleman ES, Kemppainen RJ, Judd RL. Regulation of adiponectin secretion by endothelin-1. Biochem Biophys Res Commun 2003; 312:945-949.
175. Xiong Y, Tanaka H, Richardson JA, et al. Endothelin-1 stimulates leptin production in adipocytes. J Biol Chem 2001; 276:28471-28477.
176. Zhong Q, Lin CY, Clarke KJ, Kemppainen RJ, Schwartz DD, Judd RL. Endothelin-1 inhibits resistin secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 296:383-387.
177. Matsuda K, Teragawa H, Fukuda Y, Nakagawa K, Higashi Y, Chayama K. Leptin causes nitric-oxide independent coronary artery vasodilation in humans. Hypertens Res 2003; 26:147-152.
178. Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001; 276:41245-41254.
179. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278:45021-45026.
180. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003; 46:1543-1549.
181. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138:S419-S420.
182. Chambers JC, Eda S, Bassett P, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104:145-150.
183. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: metaanalyses of prospective studies. JAMA 1998; 279:1477-1482.
184. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J 2002; 144:233-238.
185. Retterstol L, Eikvar L, Berg K. A twin study of C-Reactive Protein compared to other risk factors for coronary heart disease. Atherosclerosis 2003; 169:279-282.
186. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391-397.
187. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
188. van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 2003; 163:1323-1328.
189. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19:972-978.
190. Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102:42-47.
191. Hak AE, Pols HA, Stehouwer CD, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 2001; 86:4398-4405.
192. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25:2016-2021.
193. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999; 22:1971-1977.
194. Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999; 19:1986-1991.
195. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated Creactive protein levels in overweight and obese adults. JAMA 1999; 282:2131-2135.
196. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52:812-817.
197. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148:209-214.
198. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated Creactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108:1930-1932.
199. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002; 25:542-549.
200. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
201. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289:1799-1804.
202. Sasaki S, Higashi Y, Nakagawa K, et al. A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. Am J Hypertens 2002; 15:302-309.